BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AZD5863 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of AZD5863\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06005493-11175@assetmemo.bio
DTSTAMP:20261121T004548Z
DTSTART;VALUE=DATE:20290316
DTEND;VALUE=DATE:20290317
SUMMARY:AZD5863: Phase 1/2 readout est. (NCT06005493)
DESCRIPTION:AZD5863\, phase 1/2.\nStudy: Study of AZD5863 in Adult Particip
 ants With Advanced or Metastatic Solid Tumors\nEstimated primary completio
 n: 16 March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azd
 5863#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06005493
URL:https://assetmemo.bio/drug/azd5863#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
